Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Autologous BCMA CAR-T(The First Affiliated Hospital of Xiamen University) in Multiple Myeloma: NCT06581640 Clinical Landscape Report 2026
16 October 2026
NCT06581640 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rivaroxaban in Multiple Myeloma: NCT06580223 Clinical Landscape Report 2026
16 October 2026
NCT06580223 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rapcabtagene autoleucel in Lupus Nephritis: NCT06581198 Clinical Landscape Report 2026
16 October 2026
NCT06581198 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Advanced Endometrial Carcinoma: NCT06584032 Clinical Landscape Report 2026
16 October 2026
NCT06584032 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti CD19 chimeric antigen receptor T cell therapy(Beijing Boren Hospital) in Lupus Nephritis: NCT06585514 Clinical Landscape Report 2026
16 October 2026
NCT06585514 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tranexamic Acid in Acute Myeloid Leukemia: NCT06599762 Clinical Landscape Report 2026
16 October 2026
NCT06599762 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JNJ-87562761 in Relapse multiple myeloma: NCT06604715 Clinical Landscape Report 2026
16 October 2026
NCT06604715 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
OXS-C3550 in Acute Myeloid Leukemia: NCT06594445 Clinical Landscape Report 2026
16 October 2026
NCT06594445 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in Acute Myeloid Leukemia: NCT06598969 Clinical Landscape Report 2026
16 October 2026
NCT06598969 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Advanced Malignant Solid Neoplasm: NCT06598371 Clinical Landscape Report 2026
16 October 2026
NCT06598371 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06598384 Clinical Landscape Report 2026
16 October 2026
NCT06598384 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BA-1302 in Pancreatic adenocarcinoma: NCT06596915 Clinical Landscape Report 2026
16 October 2026
NCT06596915 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.